
bioventus®
Innovations For Active Healing

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning our industry, competitive position and the markets in which Bioventus Inc. operates; business strategy, position and operations; expected sales trends, opportunities and growth; the ongoing COVID-19 pandemic; the expected benefits and impact of Bioventus' products, including in certain regions, and biologic drug candidates; and benefits of the Bioness acquisition. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Important factors that could cause actual results to differ materially from those contemplated in this presentation include, but are not limited to, statements about the adverse impacts on our business as a result of the COVID-19 pandemic; our dependence on a limited number of products; our ability to develop, acquire and commercialize new products, line extensions or expanded indications; the continued and future acceptance of our existing portfolio of products and any new products, line extensions or expanded indications by physicians, patients, third-party payers and others in the medical community; our ability to differentiate the hyaluronic acid ("HA") viscosupplementation therapies we own or distribute from alternative therapies for the treatment of osteoarthritic; the proposed down-classification of non-invasive bone growth stimulators, including our Exogen system, by the FDA; our ability to achieve and maintain adequate levels of coverage and/or reimbursement for our products, the procedures using our products, or any future products we may seek to commercialize; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; competition against other companies; the negative impact on our ability to market our HA products due to the reclassification of HA products from medical devices to drugs in the United States by the FDA; our ability to attract, retain and motivate our senior management and qualified personnel; our ability to continue to research, develop and manufacture our products if our facilities are damaged or become inoperable; failure to comply with the extensive government regulations related to our products and operations; enforcement actions if we engage in improper claims submission practices or in improper marketing or promotion of our products; the FDA regulatory process and our ability to obtain and maintain required regulatory clearances and approvals; failure to comply with the government regulations that apply to our human cells, tissues and cellular or tissue-based products; the clinical studies of any of our future products that do not product produce results necessary to support regulatory clearance or approval in the United States or elsewhere; and the other risks identified in the Risk Factors section of the Company's public filings with the Securities and Exchange Commission ("SEC"), including Bioventus' Annual Report on Form 10-K for the year ended December 31, 2020, as such factors may be updated from time to time in Bioventus' other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investor Relations page of Bioventus' website at ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ materially from those set forth in the forward-looking statements.

Use of Estimates

Unless otherwise indicated, information contained in this presentation concerning our industry, competitive position and the markets in which Bioventus Inc. operates is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third-party sources, as well as data from our internal research, and are based on assumptions made by the Company upon reviewing such data, and the Company's experience in, and knowledge of, such industry and markets, which the Company believes to be reasonable. In addition, projections, assumptions and estimates of the future performance of the industry in which the Company operates and its future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described above. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company.

bioventus®

Innovations For Active Healing

Q1 2021 Results

Bioventus delivered better-than-expected first quarter revenue results, while also completing an important strategic acquisition.

Our acquisition of Bioness, a global leader in neuromodulation and advanced rehabilitation medical devices, significantly expands our total addressable market in excess of $8 billion.

The Bioness acquisition is a great example of how we plan to leverage our in-organic business development strategy to enhance our multi-year growth profile and leverage our significant customer presence across orthopedics, broaden our portfolio and increase our global footprint.

Ken Reali

Chief Executive Officer, Bioventus

bioventus®

Innovations For Active Healing

Revenue Snapshot

Total Q1 2021 Revenue **+4.0% y.o.y.**

$81.8M

Total Q1 2020 Revenue

$78.6M

US Revenue Growth

+3.6% y.o.y.

International Revenue Growth

+8.5% y.o.y.

bioventus®

Innovations For Active Healing

Revenue Breakdown

Pain Treatments and Joint Preservation Revenues **+ 0.6% y.o.y.**

Q1 2021: **$41.5M**

Q1 2020: **$41.3M**

Bone Graft Substitutes Revenues **+32.6% y.o.y.**

Q1 2021: **$18.4M**

Q1 2020: **$13.9M**

Restorative Therapies Revenues **–7.0% y.o.y.**

Q1 2021: **$21.8M**

Q1 2020: **$23.5M**

bioventus®

Innovations For Active Healing

Bioventus News

On February 16, 2021, the Company successfully closed its **initial public offering ("IPO").**

On March 11, 2021, the Company announced that the **first patients had been enrolled and dosed** in its Phase 1 open-label, dose-escalation study of **MOTYS (PTP-001).**

On March 30, 2021, the Company announced the **acquisition of Bioness**, a global leader in neuromodulation and advanced rehabilitation medical devices

bioventus®
Innovations For Active Healing

Acquisition - Background

Mission Statement: *Help improve lives and restore function for those living with neurological deficit and peripheral pain*

Rehabilitation *(85% of revenue)*

Restore extremity utilization for neuro and ortho patients through Functional electrical stimulation (FES), Robotic-Assist gate safety systems, and software learning platforms

Peripheral Nerve Stimulation (PNS) *(15% of revenue)*

StimRouter

TalisMann

Treat post-surgical pain as part of medtech's high-growth neuromodulation category

Key Strengths

- **~$8B+ global TAM**
  - **~$6B Post Surgical Pain**
  - **~$2B Rehabilitation**
- **Alternative to Opioids in pain**
- **Major upcoming launch: TalisMann – implantable peripheral nerve stimulation**
- **17 of US top 20 Rehab hosp. as customers**
- **Synergistic fit with Bioventus**

Financial snapshot & footprint

~$40M 2020A Revenue
~15% 2016-2019 Revenue CAGR

6 FDA Approved Devices

3 locations (US, Israel, Netherlands)

bioventus
Innovations For Active Healing

Bioventus & Bioness

	Pain Treatments & Joint Preservation	Restorative Therapies	Bone Graft Substitutes
Products	DUROLANE hyaluronic acid, stabilized single injection; GELSYN-3 3 injection hyaluronic acid treatment; SUPARTZ FX sodium hyaluronate; Bioness LiveOn Talisman L360 StimRouter 	exogen ultrasound bone healing system  Bioness LiveOn L300 GO H200 Wireless BITS  c3 vector	osteoamp Allogeneic Morphogenetic Proteins; signafuse Bioactive Bone Graft; interface Bioactive Bone Graft; cellxtract Autologous Cell and Bone Marrow Extraction
2021 Revenue (approx.)	**~$200M**	**~$125M**	**~$75M**
TAM	*$2B Global HA* *$6B Global PNS* **~$8B**	*$350M Global Bone Healing* *$1.75B Global Rehabilitation* **~$2B**	*$2.7B US Orthobiologics* **~$2.7B**
Sales Force	**~300 Direct Reps**		**170 Independent Distributors** **15 Direct Sales Reps**

bioventus® Active Healing Through Orthobiologics

~$400M Rev.

~$12B TAM

Bioness significantly expands Bioventus' ability to improve the lives of patients…

Osteoarthritis	Fracture Treatment	Spinal Fusions	Post-Surgical Pain	Post Stroke	Multiple Sclerosis	Traumatic Brain Injury	Spinal Cord Injury	Cerebral Palsy

bioventus® Innovations For Active Healing


bioventus®
Innovations For Active Healing